ADMA Biologics, Inc. Overview
Pro stress-test →ADMA Biologics is an end-to-end commercial biopharmaceutical company committed to manufacturing, marketing, and developing specialty biologic products for the prevention and treatment of infectious diseases in immune compromised and other patients at risk for infection. The company demonstrated strong execution in 2025 with preliminary full-year revenue of $510-511 million.
Strategic Profile
Pro stress-test →ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation facility in Boca Raton, Florida, and operates as an FDA-approved source plasma collector in the U.S. through its ADMA BioCenters subsidiary. This integrated, U.S.-based supply chain provides regulatory resilience and operational control in a specialized immunotherapy market.
Competitive Landscape
Pro stress-test →ADMA competes in the specialty plasma-derived biologics market for immune deficiencies and infectious diseases. Key competitors include other plasma-derived immunoglobulin manufacturers such as Grifols, CSL Limited, and emerging therapies in intravenous immunoglobulin. ADMA's integrated U.S.-based manufacturing and supply chain provides a structural differentiation.
Industry Context
ADMA Biologics, Inc. operates in Biopharmaceutical - Specialty Plasma-Derived Biologics.
Key facts
Founded: 2004 · Headquarters: Ramsey, New Jersey & Boca Raton, Florida · Revenue: $510-511M (FY 2025 preliminary) · Market cap: $3.2B